Semaglutide

Quickstart Highlights

Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist with a prolonged half-life of approximately 7 days, approved for chronic weight management and glycemic control. The extended half-life enables once-weekly subcutaneous dosing, which is the standard clinical approach. This educational protocol presents a gradual weekly titration from 0.25 mg up to a maintenance dose of 2.4 mg over 16+ weeks, following the FDA-label schedule. The 10 mg vial is reconstituted with 2.0 mL bacteriostatic water for 5 mg/mL, the community-standard dilution at this vial size, which gives a whole number of insulin-syringe units at every step.

• Reconstitute: Add 2 mL bacteriostatic water → 5 mg/mL concentration.
• Dose range: 250 mcg–2.4 mg once weekly (gradual escalation protocol).
• Easy measuring: At 5 mg/mL, 1 unit = 0.01 mL = 50 mcg on a U-100 insulin syringe.
• Storage: Lyophilized: freeze at −20 °C (−4 °F); after reconstitution, refrigerate at 2–8 °C (35.6–46.4 °F) and use within 28 days.

Protocol Overview

Concise summary of the once-weekly regimen.

• Goal: Support chronic weight management through GLP-1 receptor activation, leading to reduced appetite and improved metabolic parameters.
• Schedule: Weekly subcutaneous injections for 16–20+ weeks with gradual dose escalation, continued without an off-period.
• Dose Range: 250 mcg (0.25 mg) to 2400 mcg (2.4 mg) weekly with stepwise titration every 4 weeks to improve tolerability.
• Reconstitution: 2 mL per 10 mg vial (5 mg/mL) for accurate unit measurements on standard insulin syringes.
• Storage: Lyophilized frozen at −20 °C (−4 °F); reconstituted refrigerated at 2–8 °C (35.6–46.4 °F); use within 28 days; avoid repeated freeze–thaw cycles.
• Evidence: FDA label (Wegovy/Ozempic) and large human RCTs (STEP, SELECT, FLOW) support the schedule, and every source reviewed matches the 4-week escalation; confidence is high. The 2.0 mL vial-handling convention is community and vendor practice, not label.

Dosing Protocol

Suggested weekly titration approach based on clinical approval and studies.

• Weeks 1–4: 250 mcg (0.25 mg) once weekly to establish baseline tolerance.
• Weeks 5–8: 500 mcg (0.5 mg) once weekly.
• Weeks 9–12: 1000 mcg (1.0 mg) once weekly.
• Weeks 13–16: 1700 mcg (1.7 mg) once weekly.
• Weeks 17+ (Maintenance): 2400 mcg (2.4 mg) once weekly as the target maintenance dose; the label allows holding at 1.7 mg if 2.4 mg is not tolerated.
• Frequency: Once per week (subcutaneous injection).
• Timing: Administer on the same day each week at any time, with or without meals; rotate injection sites to reduce local irritation.
• Titration: Hold a step for 4 more weeks if gastrointestinal effects are unmanageable; do not escalate faster than every 4 weeks.
• Cycle: Continuous; no off-period is described in the label or in any source.

Storage Instructions

Proper storage preserves product quality and efficacy.

• Lyophilized (powder): Store at −20 °C (−4 °F) in a cool, dry place protected from light. For short-term storage (under a few months), 2–8 °C (35.6–46.4 °F) refrigeration is acceptable. Avoid humidity to prevent peptide degradation.
• Reconstituted (solution): Refrigerate at 2–8 °C (35.6–46.4 °F) and do not freeze. Use within 28 days for maximum potency and safety; the benzyl alcohol in bacteriostatic water inhibits bacterial growth, but solutions should still be discarded after approximately 4 weeks.
• Allow vials to reach room temperature before opening to minimize condensation uptake.
• Use only bacteriostatic water (0.9% benzyl alcohol) for a multi-dose vial; plain sterile water limits the reconstituted vial to about 24 hours.

Important Notes

Practical considerations for consistency and safety.

• Use new sterile insulin syringes for each injection; dispose in a proper sharps container.
• Rotate injection sites systematically (abdomen, thighs, upper arms) to reduce local irritation and avoid lipohypertrophy.
• Inject slowly and steadily; wait a few seconds before withdrawing the needle to ensure complete delivery.
• Administer on the same day each week for consistency. Label missed-dose rule: inject if the next scheduled dose is more than 2 days away, otherwise skip; if 2 or more consecutive doses are missed, restarting the titration is described.
• GLP-1 receptor agonists commonly cause gastrointestinal side effects (nausea, vomiting); the 4-week steps exist to minimize these, and a step may be held for a further 4 weeks before advancing.
• Semaglutide is an approved drug in Canada and the US (Ozempic/Wegovy); lyophilized research vials fall outside the approved product and are sold research-use-only, and Health Canada restricts compounding of semaglutide. The label carries a boxed warning for thyroid C-cell tumors in rodents and is contraindicated with a personal or family history of medullary thyroid carcinoma or MEN2.
• At 5 mg/mL every label dose is a whole number of units (5, 10, 20, 34 and 48 units), all within a 1 mL syringe and the V1 pen’s 80-unit setting. Keep the same 2.0 mL convention for every vial in a course; changing concentration mid-course is a recognized source of dosing error.
• Vial yield at the 10 mg size: because reconstituted solution is discarded after 28 days, one vial is opened per 4-week block (1, 2, 4, 6.8 and 9.6 mg used in successive blocks), so the 16-week titration uses 13.8 mg across 4 vials and each further 4 weeks at 2.4 mg uses 9.6 mg of one vial (4 doses per vial). The 10 mg size closely matches a 4-week maintenance block; a larger vial would leave more solution to discard under the 28-day rule.

How This Works

Semaglutide is a GLP-1 receptor agonist with 94% sequence homology to native human GLP-1. It promotes weight loss through multiple mechanisms: reducing appetite and food intake via GLP-1 receptors in the hypothalamus, slowing gastric emptying, and improving glycemic control through glucose-dependent insulin secretion with reduced glucagon release. The extended half-life of approximately 7 days comes from a C18 fatty-acid side chain that binds albumin and from resistance to DPP-4 degradation, enabling convenient once-weekly dosing. Clinical trials have demonstrated significant weight loss in individuals with obesity when combined with lifestyle interventions: in STEP-1, mean weight loss was 14.9% at 68 weeks on 2.4 mg versus 2.4% with placebo, and the SELECT outcome trial recorded a 20% reduction in major adverse cardiovascular events. The weekly 2.4 mg maintenance dose is FDA-approved for chronic weight management and represents the standard clinical approach; the slow 4-week titration limits gastrointestinal effects.

Potential Benefits & Side Effects

Observations from clinical literature and regulatory approvals.

Potential Benefits:

• Significant weight loss in clinical trials: 14.9% mean body-weight reduction at 68 weeks on 2.4 mg weekly in STEP-1, with 50.5% of participants losing 15% or more.
• Improved glycemic control through enhanced glucose-dependent insulin secretion and reduced glucagon secretion, with low hypoglycemia risk as monotherapy.
• Reduced appetite and food intake via central nervous system GLP-1 receptor activation and slowed gastric emptying.
• Cardiovascular benefits demonstrated in the SELECT outcome trial (20% reduction in major adverse cardiovascular events) and kidney protection in FLOW (24% reduction in major kidney outcomes in type 2 diabetes with chronic kidney disease).
• Convenient once-weekly dosing improves adherence compared to daily regimens.

Potential Side Effects:

• Gastrointestinal effects (most common): nausea 44%, diarrhea 30%, vomiting 24%, constipation 24% and abdominal pain 20% on the label; typically mild to moderate and concentrated during titration.
• Headache (14%) and fatigue (11%); injection-site redness, swelling or irritation (generally mild and transient).
• Hypoglycemia risk when combined with insulin or sulfonylureas; less common with semaglutide monotherapy due to the glucose-dependent mechanism.
• Gallbladder events (cholelithiasis 2.6% versus 1.2%), pancreatitis (under 0.4%) and a resting heart-rate increase of 2–4 bpm.
• Boxed warning: thyroid C-cell tumors observed in rodent studies (relevance to humans uncertain); contraindicated with a personal or family history of medullary thyroid carcinoma or MEN2, prior serious hypersensitivity, and not for use in pregnancy.

Lifestyle Factors

Complementary strategies for optimal outcomes with GLP-1 therapy.

• Maintain a balanced, calorie-controlled diet with adequate protein intake (1.2–1.6 g/kg body weight) to preserve lean muscle mass during weight loss.
• Combine regular physical activity including both resistance training (2–3 days per week) and aerobic exercise (150+ minutes per week) to reinforce metabolic adaptations and improve body composition.
• Prioritize consistent sleep (7–9 hours nightly) and effective stress management to support adherence and metabolic health.
• Stay well-hydrated (8–10 glasses of water daily), especially if experiencing gastrointestinal side effects.
• Monitor progress through regular weigh-ins, body measurements, photos, and consultation with healthcare providers.
• Consider working with a registered dietitian for personalized nutrition guidance during weight loss.

Injection Technique

General subcutaneous injection guidance from clinical best-practice resources.

• Clean the vial stopper and chosen skin site with separate alcohol swabs; allow both to dry completely before proceeding.
• Pinch a fold of skin between your fingers; insert the needle at a 45–90° angle into the subcutaneous tissue (fatty layer, not muscle).
• Do not aspirate (pull back the plunger) when giving a subcutaneous injection.
• Inject the solution slowly and steadily; wait at least 6 seconds after injection before withdrawing the needle to ensure complete delivery and minimize leakage.
• Withdraw the needle and apply light pressure with a clean swab; avoid rubbing vigorously.
• Rotate injection sites systematically (abdomen, thighs, upper arms) to prevent lipohypertrophy and maintain consistent absorption.
• Dispose of used syringes and needles immediately in a proper sharps container.

Recommended Source

We recommend Amino Labs for high-purity Semaglutide (10 mg vials).

Note: Product availability and specifications subject to change. Verify current product details on supplier website.

Shop at Amino Labs